Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Total Current Liabilities (2016 - 2025)

Tandem Diabetes Care's Total Current Liabilities history spans 13 years, with the latest figure at $242.7 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 1.75% year-over-year to $242.7 million; the TTM value through Dec 2025 reached $242.7 million, down 1.75%, while the annual FY2025 figure was $242.7 million, 1.75% down from the prior year.
  • Total Current Liabilities reached $242.7 million in Q4 2025 per TNDM's latest filing, down from $252.5 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $288.2 million in Q1 2025 to a low of $103.4 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $188.8 million, with a median of $180.9 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: fell 4.89% in 2021, then soared 49.34% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $131.9 million in 2021, then increased by 25.36% to $165.3 million in 2022, then increased by 18.13% to $195.3 million in 2023, then increased by 26.52% to $247.0 million in 2024, then dropped by 1.75% to $242.7 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Total Current Liabilities are $242.7 million (Q4 2025), $252.5 million (Q3 2025), and $251.7 million (Q2 2025).